Literature DB >> 16531561

Systemic suppression of interferon-gamma responses in Buruli ulcer patients resolves after surgical excision of the lesions caused by the extracellular pathogen Mycobacterium ulcerans.

Dorothy Yeboah-Manu1, Elisabetta Peduzzi, Ernestina Mensah-Quainoo, Adwoa Asante-Poku, David Ofori-Adjei, Gerd Pluschke, Claudia A Daubenberger.   

Abstract

Buruli ulcer (BU), caused by Mycobacterium ulcerans, is the third most common mycobacterial infection in immunocompetent humans besides tuberculosis and leprosy. We have compared by ex vivo enzyme-linked immunospot analysis interferon-gamma (IFN-gamma) responses in peripheral blood mononuclear cells (PBMC) from BU patients, household contacts, and individuals living in an adjacent M. ulcerans nonendemic region. PBMC were stimulated with purified protein derivative (PPD) and nonmycobacterial antigens such as reconstituted influenza virus particles and isopentenyl-pyrophosphate. With all three antigens, the number of IFN-gamma spot-forming units was reduced significantly in BU patients compared with the controls from a nonendemic area. This demonstrates for the first time that M. ulcerans infection-associated systemic reduction in IFN-gamma responses is not confined to stimulation with live or dead mycobacteria and their products but extends to other antigens. Interleukin (IL)-12 secretion by PPD-stimulated PBMC was not reduced in BU patients, indicating that reduction in IFN-gamma responses was not caused by diminished IL-12 production. Several months after surgical excision of BU lesions, IFN-gamma responses of BU patients against all antigens used for stimulation recovered significantly, indicating that the measured systemic immunosuppression was not the consequence of a genetic defect in T cell function predisposing for BU but is rather related to the presence of M. ulcerans bacteria.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16531561     DOI: 10.1189/jlb.1005581

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  20 in total

1.  Mycobacterium ulcerans triggers T-cell immunity followed by local and regional but not systemic immunosuppression.

Authors:  Alexandra G Fraga; Andrea Cruz; Teresa G Martins; Egídio Torrado; Margarida Saraiva; Daniela R Pereira; Wayne M Meyers; Françoise Portaels; Manuel T Silva; António G Castro; Jorge Pedrosa
Journal:  Infect Immun       Date:  2010-10-25       Impact factor: 3.441

Review 2.  Pathogenesis of skin ulcers: lessons from the Mycobacterium ulcerans and Leishmania spp. pathogens.

Authors:  Laure Guenin-Macé; Reid Oldenburg; Fabrice Chrétien; Caroline Demangel
Journal:  Cell Mol Life Sci       Date:  2014-01-21       Impact factor: 9.261

3.  Challenges Associated with Management of Buruli Ulcer/Human Immunodeficiency Virus Coinfection in a Treatment Center in Ghana: A Case Series Study.

Authors:  Joseph Tuffour; Evelyn Owusu-Mireku; Marie-Therese Ruf; Samuel Aboagye; Grace Kpeli; Victor Akuoku; Janet Pereko; Albert Paintsil; Kofi Bonney; William Ampofo; Gerd Pluschke; Dorothy Yeboah-Manu
Journal:  Am J Trop Med Hyg       Date:  2015-06-08       Impact factor: 2.345

Review 4.  Buruli ulcer: reductive evolution enhances pathogenicity of Mycobacterium ulcerans.

Authors:  Caroline Demangel; Timothy P Stinear; Stewart T Cole
Journal:  Nat Rev Microbiol       Date:  2009-01       Impact factor: 60.633

5.  Antioxidants protect keratinocytes against M. ulcerans mycolactone cytotoxicity.

Authors:  Alvar Grönberg; Louise Zettergren; Kerstin Bergh; Mona Ståhle; Johan Heilborn; Kristian Angeby; Pamela L Small; Hannah Akuffo; Sven Britton
Journal:  PLoS One       Date:  2010-11-04       Impact factor: 3.240

6.  Cytokine production assays reveal discriminatory immune defects in adults with recurrent infections and noninfectious inflammation.

Authors:  Jaap Ten Oever; Frank L van de Veerdonk; Leo A B Joosten; Anna Simon; Reinout van Crevel; Bart-Jan Kullberg; Inge C Gyssens; Jos W M van der Meer; Marcel van Deuren; Mihai G Netea
Journal:  Clin Vaccine Immunol       Date:  2014-05-28

7.  Systemic and local interferon-gamma production following Mycobacterium ulcerans infection.

Authors:  H S Schipper; B Rutgers; M G Huitema; S N Etuaful; B D Westenbrink; P C Limburg; W Timens; T S van der Werf
Journal:  Clin Exp Immunol       Date:  2007-09-27       Impact factor: 4.330

Review 8.  Buruli ulcer disease: prospects for a vaccine.

Authors:  Kris Huygen; Ohene Adjei; Dissou Affolabi; Gisela Bretzel; Caroline Demangel; Bernhard Fleischer; Roch Christian Johnson; Jorge Pedrosa; Delphin M Phanzu; Richard O Phillips; Gerd Pluschke; Vera Siegmund; Mahavir Singh; Tjip S van der Werf; Mark Wansbrough-Jones; Françoise Portaels
Journal:  Med Microbiol Immunol       Date:  2009-02-07       Impact factor: 3.402

9.  Dynamics of the cytokine response to Mycobacterium ulcerans during antibiotic treatment for M. ulcerans disease (Buruli ulcer) in humans.

Authors:  F S Sarfo; R O Phillips; E Ampadu; F Sarpong; E Adentwe; M Wansbrough-Jones
Journal:  Clin Vaccine Immunol       Date:  2008-11-12

10.  Mycolactone diffuses into the peripheral blood of Buruli ulcer patients--implications for diagnosis and disease monitoring.

Authors:  Fred S Sarfo; Fabien Le Chevalier; N'Guetta Aka; Richard O Phillips; Yaw Amoako; Ivo G Boneca; Pascal Lenormand; Mireille Dosso; Mark Wansbrough-Jones; Romain Veyron-Churlet; Laure Guenin-Macé; Caroline Demangel
Journal:  PLoS Negl Trop Dis       Date:  2011-07-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.